Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis
Journal of Clinical Lipidology · 2026-04 · 20 (4) · 738-749
DOI: 10.1016/j.jacl.2026.02.006 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Clinical Lipidology, 2026-04. Verfasst von Dinesh K Kalra und 7 weiteren Autor:innen. Beteiligte Einrichtung: Lipid Clinic and Division of Cardiology, University of Louisville School of Medicine, Louisville, KY, USA (Kalra). Electronic address: dinesh.kalra@l…. Hauptthemen laut MEDLINE: Cholesterol, LDL, Cardiovascular Diseases, Primary Prevention, Anticholesteremic Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Esperion Therapeutics Inc.
Abstract (Originalsprache)
BACKGROUND: Analyses of statin trials by the Cholesterol Treatment Trialists' Collaboration have suggested larger relative risk reduction (RRR) for major adverse cardiovascular events (MACE) per 1 mmol/L (38.7 mg/dL) low-density lipoprotein cholesterol (LDL-C) lowering in primary prevention than in secondary prevention. However, controversy remains about the value of LDL-C lowering in primary prevention. OBJECTIVE: This meta-analysis examined the relationship between LDL-C reduction and MACE risk in primary prevention with statin and nonstatin LDL-C-lowering therapies in cardiovascular outcomes trials (CVOTs). METHODS: PubMed and Cochrane Central Register of Controlled Trials were searched from inception through August 26, 2025. The primary endpoint was the pooled RRR vs controls for 4-point composite MACE (coronary heart disease death, nonfatal myocardial infarction, fatal and nonfatal stroke, and coronary revascularization) per 1 mmol/L LDL-C lowering. RESULTS: Eleven CVOTs of solely primary prevention participants (n = 74,466) and 3 in which >80% of participants were primary prevention (n = 24,071) were identified (11 statin, 1 bempedoic acid, 1 ezetimibe, 1 statin+ezetimibe). In 13 trials, the pooled mean difference between groups in LDL-C reduction was 1.00 mmol/L (95% CI: 0.82-1.18 mmol/L) with a pooled estimate of 30% (relative risk: 0.70; 95% CI: 0.67-0.74) RRR for 4-point MACE per 1 mmol/L LDL-C reduction vs control. CONCLUSION: In CVOTs of solely or predominantly primary prevention participants, each 1 mmol/L reduction in LDL-C was associated with a 30% RRR in 4-point MACE. These results strengthen the evidence and rationale for the benefits of LDL-C lowering in primary prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lipid Clinic and Division of Cardiology, University of Louisville School of Medicine, Louisville, KY, USA (Kalra). Electronic address: dinesh.kalra@louisville.edu.
- Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK (Ray). Electronic address: k.ray@imperial.ac.uk.
- Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA (Bajaj). Electronic address: abajaj@pennmedicine.upenn.edu.
- Department of Family Medicine, University of California Irvine Medical Center, Orange, CA, USA (Kushner). Electronic address: pkushner@hs.uci.edu.
- Midwest Biomedical Research, Addison, IL, USA (Wilcox, Dicklin, Kirkpatrick, and Maki). Electronic address: mwilcox@mbclinicalresearch.com.
- Midwest Biomedical Research, Addison, IL, USA (Wilcox, Dicklin, Kirkpatrick, and Maki). Electronic address: mdicklin@mbclinicalresearch.com.
Förderung
- Esperion Therapeutics Inc
Zitieren
APA
Kalra, D. K., Ray, K. K., Bajaj, A., Kushner, P. R., Wilcox, M. L., Dicklin, M. R., Kirkpatrick, C. F., & Maki, K. C. (2026). Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis. Journal of Clinical Lipidology, 20(4), 738-749. https://doi.org/10.1016/j.jacl.2026.02.006
Vancouver
Kalra DK, Ray KK, Bajaj A, Kushner PR, Wilcox ML, Dicklin MR, et al. Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis. Journal of Clinical Lipidology. 2026;20(4):738-749. doi:10.1016/j.jacl.2026.02.006
BibTeX
@article{Kalra2026,
author = {Kalra, Dinesh K and Ray, Kausik K and Bajaj, Archna and Kushner, Pamela R and Wilcox, Meredith L and Dicklin, Mary R and Kirkpatrick, Carol F and Maki, Kevin C},
title = {Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: A meta-analysis},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {4},
pages = {738--749},
doi = {10.1016/j.jacl.2026.02.006}
}
EUVIMED